NTLA-2002: CRISPR/Cas9-Mediated Gene Knockout of *KLKB1* for Hereditary Angioedema

2021 AAAAi Annual Meeting

Jessica Seitzer | February 27, 2021

Disclosure: Employee of Intellia Therapeutics, Inc.
This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding our: plans to submit an IND or similar clinical trial application for its hereditary angioedema (“HAE”) program in the second half of 2021; plans to nominate at least one additional development candidate in 2021; advancement and expansion of our CRISPR/Cas9 technology to develop human therapeutic products, as well as our ability to maintain and expand our related intellectual property portfolio; ability to demonstrate our platform’s modularity and replicate or apply results achieved in preclinical studies, including those in our HAE program, in any future studies, including human clinical trials; ability to develop other therapeutics using CRISPR/Cas9 technology; and statements regarding the timing of regulatory filings and clinical trial execution, including dosing of patients, regarding our development programs; and the potential commercial opportunities, including value and market, for our product candidates.

Any forward-looking statements in this presentation are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to our ability to protect and maintain our intellectual property position; risks related to our relationship with third parties, including our licensors and licensees; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission (“SEC”). All information in this presentation is as of the date of the presentation, and Intellia undertakes no duty to update this information unless required by law.
NTLA-2002: CRISPR/Cas9-mediated gene knockout of *KLKB1* to treat hereditary angioedema

**J. Seitzer**¹, C. Boiselle¹, P. Cottingham¹, C. Shaw¹, R. Lescarbeau¹, C. Blanchard¹, N. Gardner¹, V. Doshi¹, K. Wood¹, S. Patil¹, M. Pink¹, A. Amaral¹, T. DiMezzo¹, S. Soukamneuth¹, J. Phillips¹, S. Burns¹; ¹Intellia Therapeutics, Cambridge, MA.

**Rationale:** Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of debilitating and potentially fatal swelling in various parts of the body including face, hand and airways. Prophylactic treatment options for HAE patients have dramatically improved in recent years, significantly reducing the frequency of attacks and overall disease burden but all require chronic, potentially life-long administration. The emergence of genome editing technologies as a new therapeutic modality offers the promise of curing many genetic diseases. To this end, Intellia Therapeutics is developing NTLA-2002, an investigational CRISPR/Cas9-based therapy targeting *KLKB1* for the treatment of HAE.

**Methods:** Guide RNA targeting human- and cynomolgus monkey-specific KLKB1 were identified and formulated using Intellia’s modular CRISPR/Cas9 lipid nanoparticle (LNP) platform technology. These formulations were evaluated in a humanized KLKB1 mouse model (huKLKB1) and the cynomolgus monkey. KLKB1 gene editing, plasma kallikrein concentration and activity, and vascular leakage were evaluated.

**Results:** In the huKLKB1 mouse, a single administration of NTLA-2002 resulted in robust *KLKB1* gene editing (~70%), subsequent reductions in total plasma kallikrein (>90%) and abrogation of captopril-induced vascular leakage. In the monkey, a single administration of cyno-specific LNP formulation resulted in robust gene editing (~70%) and reductions in both total kallikrein protein and activity (>95%). Further, these reductions have been maintained for at least 15 months in an ongoing monkey study.

**Conclusions:** A single administration of NTLA-2002 resulted in robust, durable reduction of kallikrein protein and activity, supporting further development as a potential one-time treatment option for patients with HAE.
Dysregulated Kallikrein-Bradykinin Cascade Mediates Hereditary Angioedema Attacks

C1-INH deficiency results in unregulated release and buildup of bradykinin, activating endothelial cells and leading to angioedema in potentially any part of the body.

- Attacks can occur every 7-14 days on average for untreated patients\(^1\)
- **1 in 50,000** HAE patients worldwide\(^1\)
- **Chronic dosing** is required with current treatments

Intellia’s HAE Strategy: Achieve Profound, Stable Prophylaxis by Permanently Disabling the Kallikrein Gene Using CRISPR/Cas9 Gene Editing

**KLKB1 gene**

**Serum Kallikrein**

**HAE attacks**

WITH TREATMENT

**KLKB1 gene disabled**

Reduction in serum kallikrein protein and activity levels

Prophylactic control
No HAE attacks
NTLA-2002 Prevents Vascular Leakage in huKLKB1 Captopril-Induced Permeability Mouse Model

Vascular permeability was induced thirteen days post-dose using an intraperitoneal injection of the angiotensin converting enzyme (ACE) inhibitor captopril measured by Evans Blue Dye extravasation into the colon.

1Vascular permeability was induced thirteen days post-dose using an intraperitoneal injection of the angiotensin converting enzyme (ACE) inhibitor captopril measured by Evans Blue Dye extravasation into the colon.
Achieved Sustained Therapeutically Relevant Kallikrein Activity Reduction After a Single Dose in NHPs

Kallikrein protein reduction tracks similarly to kallikrein activity reduction (data not shown).

*Banerji et al., NEJM, 2017
• NTLA-2002 employs CRISPR/Cas9 technology to **knockout the KLKB1 gene in the liver as a single course treatment for HAE.**

• Editing of KLKB1 gene in HuKLKB1 mouse model shows **dose-dependent reduction of kallikrein protein and reduction in captopril-induced vascular leakage** holding promise for preventing attacks.

• Editing of KLKB1 gene results in **therapeutically relevant reduction of kallikrein activity** in NHPs.

• **Kallikrein activity reduction sustained for at least 77 weeks** in NHPs; suggests possibility of “one-and-done” treatment.

• **NTLA-2002 is advancing toward the clinic:** Expect to submit an IND or IND-equivalent in 2H 2021